Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide Plus ADT in High-risk Biochemical Recurrence of Prostate Cancer
NCT05794906Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Apr 2023
- Primary completion
- Jul 2027
- Modality
- Orthosteric Ligands
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Darolutamide+ADT with Placebo+ADT (2 arms). Primary endpoint: Radiological Progression-Free Survival at 24 months. Started Apr 2023; status: active, not recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05794906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05794906.